Your browser is no longer supported. Please, upgrade your browser.
Settings
LIVN [NASD]
LivaNova PLC
Index- P/E- EPS (ttm)-4.29 Insider Own0.10% Shs Outstand48.65M Perf Week-3.13%
Market Cap3.20B Forward P/E32.92 EPS next Y2.02 Insider Trans0.00% Shs Float48.34M Perf Month-1.26%
Income-207.60M PEG- EPS next Q0.66 Inst Own- Short Float6.87% Perf Quarter24.75%
Sales952.30M P/S3.36 EPS this Y12.60% Inst Trans0.12% Short Ratio6.85 Perf Half Y14.93%
Book/sh27.76 P/B2.39 EPS next Y65.27% ROA-8.40% Target Price73.67 Perf Year-7.28%
Cash/sh4.73 P/C14.03 EPS next 5Y27.30% ROE-15.30% 52W Range33.40 - 77.29 Perf YTD0.35%
Dividend- P/FCF- EPS past 5Y-28.30% ROI-8.10% 52W High-14.04% Beta0.79
Dividend %- Quick Ratio1.80 Sales past 5Y30.00% Gross Margin68.30% 52W Low98.92% ATR2.66
Employees4000 Current Ratio2.40 Sales Q/Q-10.60% Oper. Margin-17.40% RSI (14)55.47 Volatility4.00% 3.88%
OptionableYes Debt/Eq0.48 EPS Q/Q-146.20% Profit Margin-21.90% Rel Volume0.56 Prev Close65.77
ShortableYes LT Debt/Eq0.47 EarningsOct 29 BMO Payout- Avg Volume484.56K Price66.44
Recom1.90 SMA20-0.20% SMA509.67% SMA20026.52% Volume272,254 Change1.02%
Jan-05-21Downgrade Needham Buy → Hold
Sep-02-20Initiated Robert W. Baird Outperform $55
Jun-26-20Reiterated Needham Buy $84 → $76
Oct-30-19Reiterated Needham Buy $91 → $88
Feb-28-19Reiterated Needham Buy $135 → $120
Nov-28-18Initiated UBS Neutral $105
Aug-02-18Reiterated Needham Buy $128 → $135
Jun-08-18Initiated Stifel Buy $115
May-31-18Reiterated Needham Buy $102 → $106
Feb-28-18Reiterated Needham Buy $97 → $104
Jan-20-21 09:00AM  
Dec-07-20 08:00AM  
Dec-04-20 09:00AM  
Dec-03-20 05:00AM  
Nov-25-20 09:00AM  
Nov-23-20 09:00AM  
Nov-10-20 09:00AM  
Nov-02-20 06:00AM  
Oct-29-20 08:00AM  
07:57AM  
07:30AM  
06:00AM  
Oct-22-20 12:34PM  
Oct-12-20 05:15PM  
09:00AM  
09:00AM  
Oct-08-20 09:13AM  
Sep-28-20 09:00AM  
Sep-16-20 11:04AM  
Sep-02-20 10:20AM  
Sep-01-20 09:00AM  
Aug-12-20 09:00AM  
Jul-29-20 02:47PM  
07:30AM  
07:17AM  
05:00AM  
Jul-22-20 12:33PM  
Jul-20-20 06:38PM  
Jul-16-20 09:00AM  
Jul-07-20 09:00AM  
Jun-29-20 09:00AM  
Jun-15-20 03:09PM  
Jun-12-20 08:30AM  
Jun-11-20 06:55AM  
06:52AM  
Jun-08-20 10:09AM  
Jun-01-20 09:00AM  
May-28-20 09:00AM  
May-20-20 09:00AM  
May-19-20 09:00AM  
May-11-20 09:00AM  
May-01-20 09:19AM  
Apr-30-20 04:31AM  
Apr-29-20 07:48AM  
07:45AM  
06:00AM  
Apr-27-20 09:00AM  
Apr-22-20 12:31PM  
09:00AM  
Mar-30-20 09:00AM  
Mar-27-20 02:32PM  
Mar-26-20 09:00AM  
Mar-09-20 09:00AM  
Feb-26-20 04:44PM  
07:30AM  
06:00AM  
06:00AM  
Feb-25-20 02:00PM  
Feb-21-20 07:54AM  
Feb-19-20 12:31PM  
09:00AM  
Jan-28-20 09:00AM  
Dec-19-19 07:27PM  
Dec-06-19 12:57PM  
Dec-05-19 09:00AM  
Nov-20-19 09:35AM  
06:12AM  
06:00AM  
Nov-19-19 09:00AM  
Nov-01-19 09:00AM  
Oct-30-19 07:30AM  
06:00AM  
Oct-29-19 09:59AM  
Oct-26-19 03:00PM  
Oct-24-19 09:00AM  
Oct-23-19 10:34AM  
09:00AM  
Oct-18-19 09:14AM  
Oct-03-19 09:00AM  
Sep-27-19 02:17PM  
Sep-13-19 09:00AM  
Sep-09-19 09:11AM  
Sep-05-19 04:15PM  
Sep-03-19 10:14AM  
Aug-30-19 09:00AM  
Jul-31-19 09:24PM  
07:30AM  
06:00AM  
Jul-30-19 09:40AM  
Jul-24-19 10:32AM  
Jul-19-19 07:57AM  
Jul-16-19 09:00AM  
Jul-15-19 08:55AM  
Jul-11-19 09:00AM  
Jun-20-19 12:08PM  
Jun-19-19 04:47PM  
Jun-17-19 09:00AM  
May-16-19 09:00AM  
May-03-19 09:00AM  
May-02-19 03:24AM  
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CVA) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC has a research collaboration with Verily to gain insights into Vagus nerve stimulation impact on difficult-to-treat depression. The company was founded in 1987 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shvartsburg AlexInterim CFODec 15Option Exercise0.0066402,201Dec 17 04:49 PM
Khoury RoyPresident, InternationalDec 15Option Exercise0.0051503,505Dec 17 04:46 PM
McDonald DamienCEONov 04Option Exercise0.0016,744064,769Nov 06 06:57 PM
Hebbelinck TruiChief Human Resources OfficerSep 15Option Exercise0.004400661Sep 17 11:07 AM
Skeffington Keyna PidcockGeneral CounselSep 15Option Exercise0.0030003,157Sep 17 11:12 AM
Khoury RoyPresident, InternationalAug 05Option Exercise0.0057303,260Aug 10 07:56 AM
Moore Daniel JeffreyDirectorJun 18Option Exercise0.002,524030,876Jun 22 09:09 PM
Saia Andrea LynnDirectorJun 18Option Exercise0.001,50004,498Jun 22 06:11 PM
ROSENTHAL ARTHUR LDirectorJun 18Option Exercise0.001,500020,115Jun 22 06:09 PM
O'Kane SharonDirectorJun 18Option Exercise0.001,50005,728Jun 22 06:06 PM
Novak Alfred JDirectorJun 18Option Exercise0.001,500012,070Jun 22 06:03 PM
KOZY WILLIAM ADirectorJun 18Option Exercise0.001,50003,076Jun 22 05:56 PM
Enxing Seng StacyDirectorJun 18Option Exercise0.001,50001,500Jun 22 05:53 PM
Bianchi FrancescoDirectorJun 18Option Exercise0.001,50003,020Jun 22 05:50 PM
MORRISON HUGH MDirectorJun 18Option Exercise0.001,50003,020Jun 22 05:44 PM
Novak Alfred JDirectorJun 16Buy46.711,00046,71310,570Jun 16 05:12 PM
Skeffington Keyna PidcockGeneral CounselJun 12Option Exercise0.001,14603,362Jun 16 05:06 PM
Huston Thad AllenChief Financial OfficerMay 23Option Exercise0.009,907031,662May 27 05:18 PM
Huston Thad AllenChief Financial OfficerMay 20Option Exercise0.001,595022,505May 21 04:04 PM
McDonald DamienCEOMay 05Option Exercise0.004,451077,932May 07 05:09 PM
Khoury RoyPresident, InternationalMay 05Option Exercise0.0045302,900May 07 05:06 PM
Dolci MarcoSVP Global Operations, R&DMay 05Option Exercise0.0056504,212May 07 05:03 PM
Huston Thad AllenChief Financial OfficerMar 30Option Exercise0.001,286021,341Apr 01 08:38 PM
Skeffington Keyna PidcockGeneral CounselMar 30Option Exercise0.0057902,489Apr 01 08:36 PM
Manko Douglas JohnChief Accounting OfficerMar 30Option Exercise0.0025703,338Apr 01 08:34 PM
Hebbelinck TruiChief Human Resources OfficerMar 30Option Exercise0.004180418Apr 01 08:31 PM
McDonald DamienCEOMar 30Option Exercise0.003,214074,992Apr 01 08:26 PM
Dolci MarcoSVP Global Operations, R&DMar 30Option Exercise0.003,29404,907Apr 01 08:24 PM
Khoury RoyPresident, InternationalMar 30Option Exercise0.0054002,701Apr 01 08:21 PM
Dolci MarcoSVP Global Operations, R&DMar 15Option Exercise0.0055902,100Mar 17 07:04 PM
McDonald DamienCEOMar 15Option Exercise0.003,182073,274Mar 17 07:02 PM
Manko Douglas JohnChief Accounting OfficerMar 15Option Exercise0.0028303,165Mar 17 07:00 PM
Khoury RoyPresident, InternationalMar 15Option Exercise0.0058902,438Mar 17 06:58 PM
Skeffington Keyna PidcockGeneral CounselMar 15Option Exercise0.0045902,126Mar 17 06:54 PM
Huston Thad AllenChief Financial OfficerMar 15Option Exercise0.001,061020,411Mar 17 06:52 PM
Manko Douglas JohnChief Accounting OfficerMar 01Option Exercise0.0075403,106Mar 03 04:39 PM
Khoury RoyPresident, InternationalMar 01Option Exercise0.001,35902,488Mar 03 04:35 PM
Dolci MarcoSVP Global Operations, R&DMar 01Option Exercise0.001,69502,309Mar 03 04:33 PM
Huston Thad AllenChief Financial OfficerMar 01Option Exercise0.004,784020,953Mar 03 04:31 PM
McDonald DamienCEOMar 01Option Exercise0.0013,352077,368Mar 03 04:28 PM
McDonald DamienCEOFeb 03Sale68.001,00068,00064,016Feb 05 12:44 PM